8ZHO image
Entry Detail
PDB ID:
8ZHO
EMDB ID:
Title:
SARS-CoV-2 S1 in complex with H18 and R1-32 Fab
Biological Source:
PDB Version:
Deposition Date:
2024-05-11
Release Date:
2024-08-21
Method Details:
Experimental Method:
Resolution:
3.54 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Spike glycoprotein
Chain IDs:A (auth: C)
Chain Length:666
Number of Molecules:1
Biological Source:Severe acute respiratory syndrome coronavirus 2
Polymer Type:polypeptide(L)
Description:Heavy chain of R1-32 Fab
Chain IDs:B (auth: D)
Chain Length:228
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Light chain of R1-32 Fab
Chain IDs:C (auth: E)
Chain Length:214
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Heavy chain of H18 Fab
Chain IDs:E (auth: H)
Chain Length:243
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Light chain of H18 Fab
Chain IDs:D (auth: L)
Chain Length:243
Number of Molecules:1
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Antibodies utilizing VL6-57 light chains target a convergent cryptic epitope on SARS-CoV-2 spike protein and potentially drive the genesis of Omicron variants.
Nat Commun 15 7585 7585 (2024)
PMID: 39217172 DOI: 10.1038/s41467-024-51770-3

Abstact

Continued evolution of SARS-CoV-2 generates variants to challenge antibody immunity established by infection and vaccination. A connection between population immunity and genesis of virus variants has long been suggested but its molecular basis remains poorly understood. Here, we identify a class of SARS-CoV-2 neutralizing public antibodies defined by their shared usage of VL6-57 light chains. Although heavy chains of diverse genotypes are utilized, convergent HCDR3 rearrangements have been observed among these public antibodies to cooperate with germline VL6-57 LCDRs to target a convergent epitope defined by RBD residues S371-S373-S375. Antibody repertoire analysis identifies that this class of VL6-57 antibodies is present in SARS-CoV-2-naive individuals and is clonally expanded in most COVID-19 patients. We confirm that Omicron-specific substitutions at S371, S373 and S375 mediate escape of antibodies of the VL6-57 class. These findings support that this class of public antibodies constitutes a potential immune pressure promoting the introduction of S371L/F-S373P-S375F in Omicron variants. The results provide further molecular evidence to support that antigenic evolution of SARS-CoV-2 is driven by antibody mediated population immunity.

Legend

Protein

Chemical

Disease

Primary Citation of related structures